Table 2.
Nominally Significant Association Results for Atypical Antipsychotics in the CATIE Trial
| Rs# | Chr | Base Pair | Minor Allele | P-valuea | FDRb | Responsec | Genetic modeld |
|---|---|---|---|---|---|---|---|
| olanzapine | |||||||
| 11960832e | 5 | 75550742 | T | 2.94E-05 | 2.18E-02 | worse | recessive |
| 3.39E-02 | 9.96E-01 | worse | additive | ||||
| 4580760 | 5 | 75476111 | A | 2.47E-03 | 9.16E-01 | better | additive |
| 3.35E-02 | 9.96E-01 | better | dominant | ||||
| 10214163f | 5 | 75330166 | C | 1.40E-02 | 9.96E-01 | worse | additive |
| 4.00E-02 | 9.96E-01 | worse | dominant | ||||
| 1995381 | 5 | 75606414 | G | 2.01E-02 | 9.96E-01 | worse | dominant |
| 2270927g | 5 | 75627466 | G | 2.47E-02 | 9.96E-01 | worse | dominant |
| 6874435 | 5 | 75610611 | G | 3.22E-02 | 9.96E-01 | worse | dominant |
| 2112865 | 5 | 75465359 | G | 4.18E-02 | 9.96E-01 | better | dominant |
| quetiapine | |||||||
| 10214163f | 5 | 75330166 | C | 4.62E-03 | 9.96E-01 | better | dominant |
| 5.90E-03 | 9.96E-01 | better | additive | ||||
| 2134227 | 5 | 75436223 | C | 7.77E-03 | 9.96E-01 | better | dominant |
| 8.32E-03 | 9.96E-01 | better | additive | ||||
| 31244g | 5 | 75630499 | A | 2.35E-02 | 9.96E-01 | worse | dominant |
| 11960832e | 5 | 75550742 | T | 4.56E-02 | 9.96E-01 | worse | recessive |
| risperidone | |||||||
| 7732173 | 5 | 75513419 | A | 1.76E-02 | 9.96E-01 | worse | recessive |
| 10514062 | 5 | 75513972 | T | 1.76E-02 | 9.96E-01 | worse | recessive |
| 2358531 | 5 | 75515542 | G | 1.76E-02 | 9.96E-01 | worse | recessive |
| 1995380 | 5 | 75548413 | C | 2.35E-02 | 9.96E-01 | better | dominant |
| 6882321 | 5 | 75599586 | C | 3.82E-02 | 9.96E-01 | better | dominant |
| ziprasidone | |||||||
| 12522597 | 5 | 75467455 | A | 1.01E-02 | 9.96E-01 | better | dominant |
| 12655684 | 5 | 75528458 | T | 3.79E-02 | 9.96E-01 | better | dominant |
| 4.95E-02 | 9.96E-01 | better | additive | ||||
The trend correlation p-value (See Material and Methods Section 2.3) For a given drug, SNPs are listed by increasing p-value. Additional nominally significant associations(s) of a SNP using a different genetic model are listed immediately following the most significant result.
False Discovery Rate (See Material and Methods Section 2.3)
Better response is defined as a greater decrease in PANSS-T than the mean for a given arm. Worse response is defined as a smaller decrease (including increases) in PANSS-T than the mean for a given arm.
Describes the type of genetic model used for the association analysis
SNP remained significant after FDR correction in the olanzapine arm and also impacted response in the quetiapine arm
Candidate SNP for nicotine impact on Parkinson’s risk (Hill-Burns et al., 2012)
SNP leads to amino acid coding change